Biopure Escapes Damages In SEC Suit, GC Doesn’t

Law360, New York (September 13, 2006, 12:00 AM EDT) -- Biopure Corp. won’t have to pay a cent to the Securities and Exchange Commission to settle allegations of issuing false and misleading public statements, though its general counsel wasn’t as lucky.

Under the settlement agreement, the company agreed to an injunction against future violations of federal securities laws for the statements it made in an effort to obtain Food and Drug Administration approval for its synthetic blood product Hemopure, the SEC said on Tuesday.

Biopure also agreed to retain an independent consultant to review the company’s...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.